Pancreatic preneoplastic lesions plasma signatures and biomarkers based on proteome profiling of mouse models

British Journal of Cancer

Volumn 113, Issue 11, 2015, Pages 1590-1598

  Ligat, Laetitia ^a   Saint Laurent, Nathalie ^a   El Mrani, Aïcha ^a   Gigoux, Véronique ^b   Al Saati, Talal ^c   Tomasini, Richard ^d   Nigri, Jérémy ^d   Dejean, Sébastien ^e   Pont, Frédéric ^a   Baer, Romain ^a   Guillermet Guibert, Julie ^a   Cordelier, Pierre ^a   Lopez, Frédéric ^a   Dufresne, Marlène ^a  

^a CANCER RESEARCH CENTER OF TOULOUSE   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c Centre Hospitalier Universitaire   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

^e INSTITUT DE MATHÉMATIQUES DE TOULOUSE   (France)

Author keywords

alpha 2 macroglobulin; biomarker; complement C3; genetically engineered mouse model; ITIH; pancreatic cancer; PanIN; proteomics

Indexed keywords

ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A4; BIOLOGICAL MARKER; COMPLEMENT COMPONENT C3; FETUIN A; FIBRONECTIN; IMMUNOGLOBULIN ALPHA CHAIN C REGION; IMMUNOGLOBULIN GAMMA 2B CHAIN C REGION; IMMUNOGLOBULIN HEAVY CHAIN V REGION MOPC 21; IMMUNOGLOBULIN MU CHAIN; INTER ALPHA TRYPSIN INHIBITOR HEAVY CHAIN 4; INTER ALPHA TRYPSIN INHIBITOR HEAVY CHAIN H1; INTER ALPHA TRYPSIN INHIBITOR HEAVY CHAIN H3; LUMICAN; PLASMA PROTEIN; PROTEOME; PROTHROMBIN; UNCLASSIFIED DRUG; PEPTIDE; TUMOR MARKER; TUMOR PROTEIN;

ACINAR CELL; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CAPILLARY ELECTROPHORESIS; CONTROLLED STUDY; GENETICALLY ENGINEERED MOUSE STRAIN; LASER MICRODISSECTION; MASS SPECTROMETRY; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS ADENOMA; PRECANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEOMICS; ANIMAL; BLOOD; CARCINOMA IN SITU; CHEMISTRY; DISEASE MODEL; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PROTEIN MICROARRAY;

ANIMALS; BIOMARKERS, TUMOR; CARCINOMA IN SITU; CARCINOMA, PANCREATIC DUCTAL; DISEASE MODELS, ANIMAL; MICE; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; PEPTIDES; PRECANCEROUS CONDITIONS; PROTEIN ARRAY ANALYSIS; PROTEOME;

EID: 84949321004     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.370     Document Type: Article

References (39)

1. Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA, Horner J, Redston MS, DePinho RA. (2003). Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 17: 3112-3126.
2. Canto MI, Hruban RH, Fishman EK, Kamel IR, Schulick R, Zhang Z, Topazian M, Takahashi N, Fletcher J, Petersen G, Klein AP, Axilbund J, Griffin C, Syngal S, Saltzman JR, Mortele KJ, Lee J, Tamm E, Vikram R, Bhosale P, Margolis D, Farrell J, Goggins M. (2012). Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 142: 796-804.
3. Cecconi D, Palmieri M, Donadelli M. (2011). Proteomics in pancreatic cancer research. Proteomics 11: 816-828.
4. Chong PK, Lee H, Zhou J, Liu SC, Loh MC, Wang TT, Chan SP, Smoot DT, Ashktorab H, So JB, Lim KH, Yeoh KG, Lim YP. (2010). ITIH3 is a potential biomarker for early detection of gastric cancer. J Proteome Res 9: 3671-3679.
5. Crnogorac-Jurcevic T, Chelala C, Barry S, Harada T, Bhakta V, Lattimore S, Jurcevic S, Bronner M, Lemoine NR, Brentnall TA. (2013). Molecular analysis of precursor lesions in familial pancreatic cancer. PLoS One 8: e54830.
6. Cui Y, Zhang D, Jia Q, Li T, Zhang W, Han J. (2009). Proteomic and tissue array profiling identifies elevated hypoxia-regulated proteins in pancreatic ductal adenocarcinoma. Cancer Invest 27: 747-755.
7. Cutts RJ, Gadaleta E, Hahn SA, Crnogorac-Jurcevic T, Lemoine NR, Chelala C. (2011). The Pancreatic Expression Database: 2011 update. Nucleic Acids Res 39: D1023-D1028.
8. Faca VM, Song KS, Wang H, Zhang Q, Krasnoselsky AL, Newcomb LF, Plentz RR, Gurumurthy S, Redston MS, Pitteri SJ, Pereira-Faca SR, Ireton RC, Katayama H, Glukhova V, Phanstiel D, Brenner DE, Anderson MA, Misek D, Scholler N, Urban ND, Barnett MJ, Edelstein C, Goodman GE, Thornquist MD, McIntosh MW, DePinho RA, Bardeesy N, Hanash SM. (2008). A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med 5: e123.
9. Fakelman F, Felix K, Buchler MW, Werner J. (2010). New pre-Analytical approach for the deep proteome analysis of sera from pancreatitis and pancreas cancer patients. Arch Physiol Biochem 116: 208-217.
10. Fiedler GM, Leichtle AB, Kase J, Baumann S, Ceglarek U, Felix K, Conrad T, Witzigmann H, Weimann A, Schutte C, Hauss J, Buchler M, Thiery J. (2009). Serum peptidome profiling revealed platelet factor 4 as a potential discriminating peptide associated with pancreatic cancer. Clin Cancer Res 15: 3812-3819.
11. Gu G, Dubauskaite J, Melton DA. (2002). Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors. Development 129: 2447-2457.
12. Hanas JS, Hocker JR, Cheung JY, Larabee JL, Lerner MR, Lightfoot SA, Morgan DL, Denson KD, Prejeant KC, Gusev Y, Smith BJ, Hanas RJ, Postier RG, Brackett DJ. (2008). Biomarker identification in human pancreatic cancer sera. Pancreas 36: 61-69.
13. Harsha HC, Kandasamy K, Ranganathan P, Rani S, Ramabadran S, Gollapudi S, Balakrishnan L, Dwivedi SB, Telikicherla D, Selvan LD, Goel R, Mathivanan S, Marimuthu A, Kashyap M, Vizza RF, Mayer RJ, Decaprio JA, Srivastava S, Hanash SM, Hruban RH, Pandey A. (2009). A compendium of potential biomarkers of pancreatic cancer. PLoS Med 6: e1000046.
14. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, Kawaguchi Y, Johann D, Liotta LA, Crawford HC, Putt ME, Jacks T, Wright CV, Hruban RH, Lowy AM, Tuveson DA. (2003). Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4: 437-450.
15. Hocker JR, Mohammed A, Aston CE, Brewer M, Lightfoot SA, Rao CV, Hanas JS. (2013). Mass profiling of serum to distinguish mice with pancreatic cancer induced by a transgenic Kras mutation. Int J Cancer 133: 2662-2671.
16. Hruban RH, Adsay NV, Albores-Saavedra J, Anver MR, Biankin AV, Boivin GP, Furth EE, Furukawa T, Klein A, Klimstra DS, Kloppel G, Lauwers GY, Longnecker DS, Luttges J, Maitra A, Offerhaus GJ, Perez-Gallego L, Redston M, Tuveson DA. (2006). Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res 66: 95-106.
17. Hung KE, Faca V, Song K, Sarracino DA, Richard LG, Krastins B, Forrester S, Porter A, Kunin A, Mahmood U, Haab BB, Hanash SM, Kucherlapati R. (2009). Comprehensive proteome analysis of an Apc mouse model uncovers proteins associated with intestinal tumorigenesis. Cancer Prev Res 2: 224-233.
18. Ivancic MM, Huttlin EL, Chen X, Pleiman JK, Irving AA, Hegeman AD, Dove WF, Sussman MR. (2013). Candidate serum biomarkers for early intestinal cancer using 15 N metabolic labeling and quantitative proteomics in the ApcMin/+ mouse. J Proteome Res 12: 4152-4166.
19. Jamieson NB, Carter CR, McKay CJ, Oien KA. (2011). Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-Analysis. Clin Cancer Res 17: 3316-3331.
20. Kolch W, Neususs C, Pelzing M, Mischak H. (2005). Capillary electrophoresismass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrom Rev 24: 959-977.
21. Koomen JM, Shih LN, Coombes KR, Li D, Xiao LC, Fidler IJ, Abbruzzese JL, Kobayashi R. (2005). Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin Cancer Res 11: 1110-1118.
22. Kuick R, Misek DE, Monsma DJ, Webb CP, Wang H, Peterson KJ, Pisano M, Omenn GS, Hanash SM. (2007). Discovery of cancer biomarkers through the use of mouse models. Cancer Lett 249: 40-48.
23. Le Cao KA, Gonzalez I, Dejean S. (2009). integrOmics: an R package to unravel relationships between two omics datasets. Bioinformatics 25: 2855-2856.
24. Matsubara J, Honda K, Ono M, Tanaka Y, Kobayashi M, Jung G, Yanagisawa K, Sakuma T, Nakamori S, Sata N, Nagai H, Ioka T, Okusaka T, Kosuge T, Tsuchida A, Shimahara M, Yasunami Y, Chiba T, Hirohashi S, Yamada T. (2011). Reduced plasma level of CXC chemokine ligand 7 in patients with pancreatic cancer. Cancer Epidemiol Biomarkers Prev 20: 160-171.
25. Mischak H, Schanstra JP. (2011). CE-MS in biomarker discovery, validation, and clinical application. Proteomics Clin Appl 5: 9-23.
26. Pan S, Chen R, Crispin DA, May D, Stevens T, McIntosh MW, Bronner MP, Ziogas A, Anton-Culver H, Brentnall TA. (2011). Protein alterations associated with pancreatic cancer and chronic pancreatitis found in human plasma using global quantitative proteomics profiling. J Proteome Res 10: 2359-2376.
27. Pan S, Chen R, Reimel BA, Crispin DA, Mirzaei H, Cooke K, Coleman JF, Lane Z, Bronner MP, Goodlett DR, McIntosh MW, Traverso W, Aebersold R, Brentnall TA. (2009). Quantitative proteomics investigation of pancreatic intraepithelial neoplasia. Electrophoresis 30: 1132-1144.
28. Sennels L, Salek M, Lomas L, Boschetti E, Righetti PG, Rappsilber J. (2007). Proteomic analysis of human blood serum using peptide library beads. J Proteome Res 6: 4055-4062.
29. Sitek B, Sipos B, Alkatout I, Poschmann G, Stephan C, Schulenborg T, Marcus K, Luttges J, Dittert DD, Baretton G, Schmiegel W, Hahn SA, Kloppel G, Meyer HE, Stuhler K. (2009). Analysis of the pancreatic tumor progression by a quantitative proteomic approach and immunhistochemical validation. J Proteome Res 8: 1647-1656.
30. Song J, Patel M, Rosenzweig CN, Chan-Li Y, Sokoll LJ, Fung ET, Choi-Miura NH, Goggins M, Chan DW, Zhang Z. (2006). Quantification of fragments of human serum inter-Alpha-Drypsin inhibitor heavy chain 4 by a surfaceenhanced laser desorption/ionization-based immunoassay. Clin Chem 52: 1045-1053.
31. Taguchi A, Politi K, Pitteri SJ, Lockwood WW, Faca VM, Kelly-Spratt K, Wong CH, Zhang Q, Chin A, Park KS, Goodman G, Gazdar AF, Sage J, Dinulescu DM, Kucherlapati R, Depinho RA, Kemp CJ, Varmus HE, Hanash SM. (2011). Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell 20: 289-299.
32. Takano S, Sogawa K, Yoshitomi H, Shida T, Mogushi K, Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Kato A, Ishihara T, Tanaka H, Yokosuka O, Nomura F, Miyazaki M. (2010). Increased circulating cell signalling phosphoproteins in sera are useful for the detection of pancreatic cancer. Br J Cancer 103: 223-231.
33. Tonack S, Aspinall-O'Dea M, Jenkins RE, Elliot V, Murray S, Lane CS, Kitteringham NR, Neoptolemos JP, Costello E. (2009). A technically detailed and pragmatic protocol for quantitative serum proteomics using iTRAQ. J Proteomics 73: 352-356.
34. Tonack S, Aspinall-O'Dea M, Neoptolemos JP, Costello E. (2009). Pancreatic cancer: proteomic approaches to a challenging disease. Pancreatology 9: 567-576.
35. Tonack S, Jenkinson C, Cox T, Elliott V, Jenkins RE, Kitteringham NR, Greenhalf W, Shaw V, Michalski CW, Friess H, Neoptolemos JP, Costello E. (2013). iTRAQ reveals candidate pancreatic cancer serum biomarkers: influence of obstructive jaundice on their performance. Br J Cancer 108: 1846-1853.
36. Turtoi A, Musmeci D, Wang Y, Dumont B, Somja J, Bevilacqua G, De Pauw E, Delvenne P, Castronovo V. (2011). Identification of novel accessible proteins bearing diagnostic and therapeutic potential in human pancreatic ductal adenocarcinoma. J Proteome Res 10: 4302-4313.
37. Vollmer M, van de Goor T. (2009). HPLC-Chip/MS technology in proteomic profiling. Methods Mol Biol 544: 3-15.
38. Wang Y, Kuramitsu Y, Ueno T, Suzuki N, Yoshino S, Iizuka N, Zhang X, Oka M, Nakamura K. (2011). Differential expression of up-regulated cofilin-1 and down-regulated cofilin-2 characteristic of pancreatic cancer tissues. Oncol Rep 26: 1595-1599.
39. Xue A, Scarlett CJ, Chung L, Butturini G, Scarpa A, Gandy R, Wilson SR, Baxter RC, Smith RC. (2010). Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis. Br J Cancer 103: 391-400.